The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Cassava Sciences (SAVA) announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet ...

Cassava Sciences’ stock plummets 85% after its Alzheimer’s treatment trial fails. Investigations and regulatory scrutiny add ...

Cassava Sciences said a study of its Alzheimer's treatment simufilam didn't meet co-primary, secondary and exploratory biomarker endpoints. Trading was halted at 7:25 a.m. ET and resumed trading at 8 ...

Following the disappointing results, Cassava stated it would halt a second late-stage trial of simufilam, as well as its open ...

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with ...